High-throughput tracking enables systematic phenotyping and drug repurposing in C. elegans disease models.

Abstract excerpt

There are thousands of Mendelian diseases with more being discovered weekly and the majority have no approved treatments. To address this need, we require scalable approaches that are relatively inexpensive compared to traditional drug development. In the absence of a validated drug target, phenotypic screening in model organisms provides a route for identifying candidate treatments. Success requires a screenable...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Caenorhabditis elegans
• Share to Disease Models, Animal
• Share to Drug Evaluation, Preclinical